92 related articles for article (PubMed ID: 21863752)
1. [Lymphoid malignancies: progress in diagnosis and treatment. Topics: I. Pathogenesis and pathophysiology--recent findings; 3. Etiology and pathogenesis of plasma cell dyscrasia including multiple myeloma].
Hattori Y
Nihon Naika Gakkai Zasshi; 2011 Jul; 100(7):1773-80. PubMed ID: 21863752
[No Abstract] [Full Text] [Related]
2. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.
Rajkumar SV
Hematology Am Soc Hematol Educ Program; 2005; ():340-5. PubMed ID: 16304401
[TBL] [Abstract][Full Text] [Related]
3. Familiality of benign and malignant paraproteinemias. A population-based cancer-registry study of multiple myeloma families.
Ogmundsdóttir HM; Haraldsdóttirm V; Jóhannesson GM; Olafsdóttir G; Bjarnadóttir K; Sigvaldason H; Tulinius H
Haematologica; 2005 Jan; 90(1):66-71. PubMed ID: 15642671
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma.
Kyle RA; Rajkumar SV
N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
[No Abstract] [Full Text] [Related]
5. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome.
Avet-Loiseau H; Facon T; Daviet A; Godon C; Rapp MJ; Harousseau JL; Grosbois B; Bataille R
Cancer Res; 1999 Sep; 59(18):4546-50. PubMed ID: 10493504
[TBL] [Abstract][Full Text] [Related]
6. Paraproteinaemias: pathophysiology.
Samson D
Schweiz Med Wochenschr; 2000 Nov; 130(44):1643-8. PubMed ID: 11103434
[TBL] [Abstract][Full Text] [Related]
7. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.
Maura F; Petljak M; Lionetti M; Cifola I; Liang W; Pinatel E; Alexandrov LB; Fullam A; Martincorena I; Dawson KJ; Angelopoulos N; Samur MK; Szalat R; Zamora J; Tarpey P; Davies H; Corradini P; Anderson KC; Minvielle S; Neri A; Avet-Loiseau H; Keats J; Campbell PJ; Munshi NC; Bolli N
Leukemia; 2018 Apr; 32(4):1044-1048. PubMed ID: 29209044
[No Abstract] [Full Text] [Related]
8. [Amylase-producing plasma cell dyscrasia. Genomic analysis in a case of intramuscular tumor formation and a review of the literature].
Hirota K; Waga K; Nagashima S; Waku S; Yamazaki T; Saito K; Furusawa S; Shishido H
Rinsho Ketsueki; 1993 Feb; 34(2):177-82. PubMed ID: 7684094
[TBL] [Abstract][Full Text] [Related]
9. Compendium of FAM46C gene mutations in plasma cell dyscrasias.
Barbieri M; Manzoni M; Fabris S; Ciceri G; Todoerti K; Simeon V; Musto P; Cortelezzi A; Baldini L; Neri A; Lionetti M
Br J Haematol; 2016 Aug; 174(4):642-5. PubMed ID: 26456599
[No Abstract] [Full Text] [Related]
10. Multiple myeloma: current perspectives.
Slovak ML
Clin Lab Med; 2011 Dec; 31(4):699-724, x. PubMed ID: 22118745
[TBL] [Abstract][Full Text] [Related]
11. Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma.
Ronchetti D; Agnelli L; Taiana E; Galletti S; Manzoni M; Todoerti K; Musto P; Strozzi F; Neri A
Oncotarget; 2016 Mar; 7(12):14814-30. PubMed ID: 26895470
[TBL] [Abstract][Full Text] [Related]
12. Familial occurrence of multiple myeloma.
Law MI
South Med J; 1976 Jan; 69(1):46-8. PubMed ID: 1246652
[TBL] [Abstract][Full Text] [Related]
13. Focus on myeloma and plasma cell disorders. 21-22 January 2005, Las Vegas, NV, USA.
Walker RC
IDrugs; 2005 Mar; 8(3):189-92. PubMed ID: 15772884
[No Abstract] [Full Text] [Related]
14. Monoclonal gammopathy and multiple myeloma: incidence of chromosomal aneuploidy detected by interphase fluorescence in situ hybridization.
Cianciulli AM; Coletta AM; Pescatore B; Greco C; Del Monte G; Leonardo C; Venturo I; Gandolfo GM
Eur J Histochem; 1997; 41 Suppl 2():157-8. PubMed ID: 9859828
[No Abstract] [Full Text] [Related]
15. Bone and paraproteinemias.
Zangari M; Zhan F; Tricot G
Curr Opin Support Palliat Care; 2010 Sep; 4(3):195-9. PubMed ID: 20657285
[TBL] [Abstract][Full Text] [Related]
16. Familial multiple myeloma.
Catovsky D
Haematologica; 2005 Jan; 90(1):3-4. PubMed ID: 15644301
[No Abstract] [Full Text] [Related]
17. RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies.
Martín P; Santón A; García-Cosío M; Bellas C
Int J Oncol; 2005 Oct; 27(4):1023-8. PubMed ID: 16142319
[TBL] [Abstract][Full Text] [Related]
18. New insights in the clinical biology of multiple myeloma.
Bataille R
Semin Hematol; 1997 Jan; 34(1 Suppl 1):23-8. PubMed ID: 9122743
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 6, tumour necrosis factor alpha and lymphotoxin alpha polymorphisms in monoclonal gammopathy of uncertain significance and multiple myeloma.
Dring AM; Davies FE; Rollinson SJ; Roddam PL; Rawstron AC; Child JA; Jack AS; Morgan GJ
Br J Haematol; 2001 Jan; 112(1):249-51. PubMed ID: 11167813
[No Abstract] [Full Text] [Related]
20. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS.
Giovanella L; Taborelli M; Ceriani L; Zucca E; Cavalli F; Delaloye AB
Nucl Med Commun; 2008 Jun; 29(6):535-41. PubMed ID: 18458600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
